Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HVIVO PLC M&A Activity 2015

Oct 19, 2015

7697_rns_2015-10-19_7d6c720a-aaa7-42f9-8a1d-bb00b74fa992.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6073C

Venn Life Sciences Holdings PLC

19 October 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

Completion of the Acquisition of Kinesis Pharma BV

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the completion of the acquisition of Kinesis Pharma BV.

The final terms of the initial consideration for the acquisition, following the adjustment mechanism set out in the sale and purchase agreement, are a cash consideration of €1,846,620 and 4,780,320 Consideration Shares representing a value of €1,477,517. 

It is expected that the Consideration Shares will be admitted to trading on AIM on Friday 23 October 2015.

Tony Richardson, Chief Executive Officer of Venn said: "We are pleased that the acquisition of Kinesis Pharma BV has completed as it has established Venn as a highly differentiated European Contract Research Organisation and is in line with Company's strategy. We look forward to offering the complete range of services to our clients allowing us to establish earlier and longer lasting client relationships. We look forward to seeing the benefits of this acquisition in the near future."

Enquiries:

Venn Life Sciences Holdings Plc
David Evans, Non-Executive Chairman Tel: +44(0) 7980 541 893
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Zeus Capital (Nominated Adviser and Co-Broker)
Andrew Jones/Phil Walker Tel: +44(0) 161 831 1512
Dominic Wilson/Alex Davies Tel: +44(0) 20 3829 5000
Hybridan LLP (Co-Broker)

Claire Louise Noyce
Tel: +44(0) 20 3764 2341
Walbrook PR Ltd Tel: +44(0)20 7933 8787 or [email protected]
Paul McManus Mob: +44(0) 7980 541 893
Lianne Cawthorne Mob: +44(0) 7584 391 303

About Venn Life Sciences:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQGGGCGUUPAGBR

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'3XpCcCeIJfKiqg2VGVlBVBEYCeJDhSh12uf-YM7GIhe75wmECl9J4ojjnsb90v2OEf1Mzevw7B-m1NCiUE_jV0t5rmmuE77g54wfCc36UNU1:RTpm2H00FXCbvxYVXv4bsrXi02oPYm1YYa5nS17q51ClApCAE1EL4JvnN90rn4cD4EURfL1w18l4O9xyzFkY8ntn1BAVX4fk32K8Adgtb181'}});//]]>